^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN1044

    i
    Other names: GEN1044, DuoBody-CD3x5T4, ABBV-GEN1044, ABBV-GMAB-1044
    Associations

    News

    Trials
    Company:
    AbbVie, Genmab
    Drug class:
    CD3 agonist, 5T4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. (PubMed, Life Sci Alliance)
    Lastly, in dissociated patient-derived tumor samples, DuoBody-CD3x5T4 activated tumor-infiltrating lymphocytes and induced tumor-cell cytotoxicity, even when most tumor-infiltrating lymphocytes expressed PD-1. These data provide an in-depth view on the mechanism of action of a CD3 bsAb in preclinical models of solid cancer.
    PK/PD data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • IFNGR1 (Interferon Gamma Receptor 1)
    |
    PD-1 expression
    |
    GEN1044